Furthermore, the dual prostaglandin-endoperoxide synthase/lipoxygenase (COX/LOX) inhibitor licofelone improved the efficacy of paclitaxel in ovarian cancer by suppressing tumor stem-like properties.7 The gene discussed is LOX; the disease is ovarian carcinoma.